Natera to Participate in Upcoming Investor Conferences
Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, has announced its participation in three major healthcare investor conferences. The company will present at the UBS Global Healthcare Conference on November 14, the Wolfe Research Healthcare Conference on November 19, and the 36th Annual Piper Sandler Healthcare Conference on December 3. All presentations will be accessible via live webcast through Natera's investor relations website, with replays available after each event.
Natera (NASDAQ: NTRA), leader nei test genetici e di DNA libero, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario. L'azienda presenterà alla UBS Global Healthcare Conference il 14 novembre, alla Wolfe Research Healthcare Conference il 19 novembre e alla 36a Annual Piper Sandler Healthcare Conference il 3 dicembre. Tutte le presentazioni saranno accessibili in diretta tramite webcast attraverso il sito delle relazioni con gli investitori di Natera, con repliche disponibili dopo ciascun evento.
Natera (NASDAQ: NTRA), líder en pruebas genéticas y de ADN libre, ha anunciado su participación en tres importantes conferencias de inversores en el sector salud. La empresa presentará en la UBS Global Healthcare Conference el 14 de noviembre, en la Wolfe Research Healthcare Conference el 19 de noviembre y en la 36.ª Conferencia Anual de Salud de Piper Sandler el 3 de diciembre. Todas las presentaciones estarán disponibles a través de una transmisión en vivo por el sitio web de relaciones con inversores de Natera, con repeticiones disponibles después de cada evento.
네이테라 (NASDAQ: NTRA)는 세포 프리 DNA 및 유전자 테스트의 선두주자로서, 세 가지 주요 의료 투자자 회의에 참가할 것이라고 발표했습니다. 이 회사는 11월 14일 UBS 글로벌 헬스케어 컨퍼런스, 11월 19일 울프 리서치 헬스케어 컨퍼런스, 그리고 12월 3일 제36회 파이퍼 샌들러 헬스케어 컨퍼런스에서 발표할 예정입니다. 모든 발표는 네이테라의 투자자 관계 웹사이트를 통해 실시간으로 시청할 수 있으며, 각 행사 후에는 다시 볼 수 있는 링크가 제공됩니다.
Natera (NASDAQ: NTRA), leader dans les tests ADN libres et génétiques, a annoncé sa participation à trois grandes conférences d'investisseurs dans le secteur de la santé. L'entreprise se présentera lors de la UBS Global Healthcare Conference le 14 novembre, de la Wolfe Research Healthcare Conference le 19 novembre et de la 36e Conférence Annuelle de Piper Sandler sur la Santé le 3 décembre. Toutes les présentations seront accessibles en direct via un webinaire sur le site des relations investisseurs de Natera, avec des rediffusions disponibles après chaque événement.
Natera (NASDAQ: NTRA), ein führendes Unternehmen im Bereich der zellfreien DNA und genetischen Tests, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im Gesundheitswesen angekündigt. Das Unternehmen wird am 14. November auf der UBS Global Healthcare Conference, am 19. November auf der Wolfe Research Healthcare Conference und am 3. Dezember auf der 36. Jahreskonferenz von Piper Sandler im Gesundheitswesen präsentieren. Alle Präsentationen werden über einen Live-Webcast auf der Website der Investor Relations von Natera zugänglich sein, mit Wiederholungen nach jeder Veranstaltung.
- None.
- None.
-
The UBS Global Healthcare Conference on Thursday, Nov. 14 at 11:00 am ET | 8:00 am PT in
Rancho Palos Verdes, CA. -
The Wolfe Research Healthcare Conference on Tuesday, Nov. 19 at 11:00 am ET | 8:00 am PT in
New York, NY . -
The 36th Annual Piper Sandler Healthcare Conference on Tuesday, Dec. 3 at 8 am ET | 5 am PT in
New York, NY .
A live webcast and audio archive of these events can be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of each event will be available shortly following the conferences.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108511749/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What investor conferences will Natera (NTRA) attend in November and December?
How can investors access Natera's (NTRA) conference presentations?
What time is Natera's (NTRA) presentation at the UBS Global Healthcare Conference?
